Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sinovac PCV13 Lot-to-Lot Consistency in Children Aged 2 to 5 Years
NCT07832500Phase 3Not yet recruiting
- Sponsor
- Sinovac Life Sciences
- Start
- Sep 2026
- Primary completion
- Mar 2027
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Sinovac PCV13 in pneumococcal infection (3 arms), sponsored by Sinovac Life Sciences. Primary endpoint: Pneumococcal serotype-specific IgG antibody geometric mean concentration at 30 days. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
Sinovac PCV13
03
Conditions
pneumococcal infection
Beyond the preview
Go deeper on NCT07832500.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07832500.